Introduction
The antiphospholipid syndrome (APS) is characterized by thrombosis and/or pregnancy morbidity with the persistent presence of antiphospholipid antibodies (aPL) [1] . Laboratory criteria include aPL detection by phospholipid-dependent coagulation tests referred to as lupus anticoagulant (LAC) or by quantitative solid phase assays measuring anti-b 2 glycoprotein I (ab2GPI) and anti-cardiolipin (aCL) IgG/IgM antibodies [1] . Given the high frequency of thrombosis irrespective of the syndrome, laboratory tests are of utmost importance for the classification of APS. Detection of aPL by solid phase assays is associated with high inter-laboratory and inter-method variation [2, 3] . Reports from external quality control programs illustrate that commercially available aPL assays produce variable results [4] [5] [6] .
In order to improve the identification of patients at risk, it was suggested that APS patients should be evaluated according to their aPL profile [1, 7] . Combined positivity for LAC, aCL and ab2GPI antibodies (i.e. triple-positivity) has been shown to be associated with a high risk of both a first thrombotic event and recurrence [8] [9] [10] . In the NOH-APS study, a large observational study, triple-positivity was a predictor for thrombosis in purely obstetric APS patients [11] . However, computed risks for thrombosis of LAC positivity and triple-positivity were globally concordant, with the exception of pulmonary embolism [11] . Despite the high correlation of triplepositives with thrombosis, the predictive value is argued to originate from LAC positivity [12] . Recently, the detection of triple-positivity (i.e. positivity for LAC, aCL and ab2GPI antibodies) was suggested to be method and platform independent [13] .
Looking at the isotype of aPL, both IgG and IgM antibodies directed against cardiolipin and b2GPI are included in the Sydney criteria [1] . However, the clinical value of IgM antibodies in thrombotic APS is debated [14] . To date, the thrombotic association of IgM antibodies in aPL profiles such as triple-positivity is not known. In this study we included 851 patients from seven European medical centers. Four solid-phase assay platforms were selected based on frequency of use and the willingness of manufacturers to provide their assays. The samples were tested with all assays at one location by a single technician.
In a retrospective multicenter study we aimed to investigate the variability in triple-positivity detection between different aPL detection platforms and the impact of the platform on the association of triple-positivity with thrombosis. In addition, we aimed to assess the added value of aPL detection in LAC-positive patients and the impact of the isotype with respect to the association with thrombosis.
Materials and methods

Study population
We included 851 patients from seven European medical centers. Classification of APS was based on the Sydney criteria [1] . Patients were classified by the local centers, resulting in 258 thrombotic APS patients (APS thrombosis), 204 patients with a history of thrombosis and negative for laboratory criteria of APS (non-APS thrombosis), 196 patients with an autoimmune disease other than APS, such as systemic lupus erythematosus (52%) and systemic sclerosis (27%), without thrombotic complications (AID controls), and 193 controls that were referred for aPL testing for other reasons than the clinical criteria of APS, including subfertility and prolonged activated partial thromboplastin time (controls). Patients were enrolled within a time-span of 1 year, with patient samples stored for less than 5 years. Thrombosis was objectively confirmed according to the Sydney criteria [1] . The majority of thrombotic APS patients received anticoagulant therapy, including vitamin K antagonists (VKAs) (46%), low-molecular-weight heparins (LMWHs) (5%) and direct oral anticoagulants (DOACs) (4%). Twentyseven patients (10%) received antiplatelet therapy and only 2% of patients with thrombotic APS received both anticoagulant and antiplatelet therapy. Details on anticoagulant and antiplatelet therapy of the remaining 84 patients are not available. Women classified with obstetrical APS were excluded. The study was approved by the local ethical committees. Lupus anticoagulant positivity was determined by the local center, according to the ISTH-SSC (International Society of Thrombosis and Haemostasis-Scientific Standardisation Subcommittee) guideline [15] Solid phase assays Commercially available solid phase assays (Table S1) , SGU or SMU). All samples were measured by the same technician and values below the calculated limit of detection (LOD) were replaced by the LOD. Manufacturer's recommended cut-off values were used upon confirmation in 20 healthy volunteers, in accordance with the ISTH-SSC guideline [16] .
Statistics
Significance of differences between aPL titers was determined with the Mann-Whitney U-test. Diagnostic efficacy was assessed within the total population by sensitivity, specificity and odds ratios (ORs) using the Statistical Package for Social Sciences (SPSS 23.0; SPSS, Chicago, IL, USA) and MedCalc Statistical Software version 17.7.2 (MedCalc Software bvba, Ostend, Belgium). Statistical significance was set at P value less than 0.05.
Results
We measured aCL IgG/IgM and ab2GPI IgG/IgM aPL in 833 individuals with a mean age of 46 years ranging from 16 to 87 years old (Table 1 ) with four commercially available assays (Table S1 ). In our study population, venous thrombosis (VT) was more common than arterial thrombosis (AT), both in the APS and control group. In addition, primary APS (PAPS) was more prevalent than APS secondary to an underlying connective tissue disorder (SAPS).
From the 851 samples tested, 274 were LAC positive, and for these triple-positivity ranged from 106 (39%) up to 146 (53%) detected by QUANTA Lite ELISA Ò and BioPlex Ò 2200, respectively (Table 2 ). In patients diag- (Table S2) .
Agreement of triple-positivity detection by solid phase assays was assessed by a 2 9 2 contingency table within the total population ( ) individuals. In patients diagnosed with thrombotic APS (n = 258) 118 triple-positives were detected by BioPlex Ò 2200, of which 86 patients were defined as triple-positive, independent of the solid phase assay used (Table 4) . On the other hand, 32 patients were defined as triple-positive by BioPlex Ò 2200 but negative by all the other tested solid phase assays (Table 4) . However, the majority of patients with The sensitivity of triple-positivity for thrombosis was low compared with LAC alone and varied from 19% (95% confidence interval [95% CI], 16-23%) up to 26% (95% CI, 22-30%) between the tested assays ( Fig. 2A) . However, higher specificity for thrombosis was obtained, ranging from 93% (95% CI, 90-95%) up to 96% (95% CI, 93-97%), as shown in Fig. 2(B) . Lupus anticoagulant positivity resulted in an OR of 3.63 (95% CI, 2.76-4.76). Triple-positivity was statistically correlated with thrombosis, independent of the solid phase assay used to detect aCL and ab2GPI IgG/IgM antibodies (Fig. 2B) . Odds ratios for thrombosis ranged from 4.3 (95% CI, 2.7-6.8) 
Discussion
Detection of aPL antibodies is accompanied by large inter-method and inter-laboratory variation [2, 4, 5, 17, 18] . Traditionally, aCL and ab2GPI antibodies are detected by ELISA. Nowadays, more advanced (automated) systems are available, which are suggested to reduce interlaboratory variation [4, 17, [19] [20] [21] . We excluded interlaboratory variation by detection of aCL and ab2GPI antibodies in the same samples at one laboratory (Ghent, Belgium), carried out by a single technician. Despite many efforts, standardization of antiphospholipid antibody (aPL) assays is far from reached as poor consensus L u p u s a n t i c o a g u l a n t L u p u s a n t i c o a g u l a n t B i o p l e x ® is obtained between assays when measuring the same sample [2, 20] . The identification of triple-positive patients was recently suggested to be less affected by inter-method variation, thereby better classifying APS patients at risk [13] . In a retrospective cross-sectional study, the authors suggested that identification of patients with triple aPL positivity is platform and method independent, having compared two methods with a different solid phase from the same manufacturer [13] . However, they found a disparity of 6 or 9 triple-positives out of 220 patients (121 with APS and 99 with systemic lupus erythematosus), depending on the cut-off value used, already suggesting the presence of patients with low levels of ab2GPI and aCL aPL titers and difficulties in reaching consensus in the classification of these patients [13, 22] . In our cohort, the highest discrepancy in number of triple-positive samples was found between BioPlex Ò 2200 and QUANTA Lite ELISA Ò , with a discrepancy of 29 triple-positives out of 202 LAC-positive samples (14%). Similar to single positivity, identification of triple-positives was found to be assay dependent. In addition, we did not assess the variation of triple-positivity detection introduced by LAC assays. Indeed, an external quality control program concluded that inter-method and inter-laboratory variation is higher in solid phase assays than in LAC detection by dilute Russell's Viper Venom Time (dRVVT) assay [3] . However, difficulties still persist in reaching consensus among weak-positive samples [2] [3] [4] 23] . The presented variation in triple-positivity detection may therefore be underestimated. A possible limitation of our study is that thrombotic patients under treatment during the time of blood collection could result in an increased risk of falsepositive LAC tests.
Samples positive for LAC, aCL and ab2GPI antibodies by one solid phase platform but not by all four tested platforms have lower median aPL titers, suggesting difficulties in consensus on positivity among low aPL titers (Fig. 1) [24] . We accept that the cut-off calculated by the 99th percentile of a normal population is the best consensus between sensitivity and specificity, and the clinical relevance of aCL and/or ab2GPI results that are below the 99th percentile needs to be further studied [25] . Few studies showed that low titers of aCL also were predictive for thrombotic recurrence [26] . In this study, we transferred the manufacturer's cut-off after confirmation, as recommend by the ISTH-SSC guidelines [16] . In terms of clinical practice, a recent questionnaire from the SSC showed that the majority of laboratories use the same approach, because only a minority of laboratories have the resources to calculate a cut-off value from at least 120 normals. With this cut-off choice applied for all platforms, the majority of discrepant samples in our study were from patients that experienced a thrombotic event (Table 4) .
A minority of non-thrombotic patients (n = 582, autoimmune disease and controls) in our study population showed triple-positivity (n = 17-28/583 or 2.9-4.8%, depending on the platform). These should be regarded as asymptomatic carriers, which is in line with the findings of Mustonen et al., who found that 5% of asymptomatic triple-positives were carriers [27] .
The association of thrombosis and single aPL positivity is debated because results are contrary. Recent studies showed that the risk of thrombotic events increases with the number of positive tests in APS patients and the creation of antibody profiles and test combinations increases the association with thrombosis [7, 8, [28] [29] [30] . On the other hand, another study showed a strong association between single aPL positivity and thrombosis in pediatric APS patients [31] . Although single positivity is not always significantly correlated with thrombosis, within the current guidelines all aPL have the same diagnostic value [1] . In our cohort, we confirmed the strong correlation between triple-positivity and thrombosis, as triple-positivity was significantly correlated with thrombosis independent of the platform used. A large observational study investigated the incidence of thrombosis in obstetric APS patients. Frequencies of thrombotic events were assessed in 517 APS patients, 279 women carrying a genetic thrombophilia polymorphism and 796 women with negative thrombophilia polymorphism results [11] . Computed risks for thrombosis of LAC positivity and triple-positivity were globally concordant [11] . However, triple-positivity was a predictor for pulmonary embolism, whereas LAC positivity alone was not [11] . In an Italian cohort, 618 patients were referred to aPL testing, of which 55% met the clinical criteria consistent with the Sapporo criteria [7] . A statistically significant correlation between LAC and thrombosis was found (OR, 4.4; 95% CI, 1.5-13.3) [7] . In triple-positive patients the association with thrombosis increased even further (OR, 33.3; 95% CI, 7.0-157.6), suggesting an additional value of triple-positivity detection in thrombotic risk stratification [7] . Patient population and aPL detection method may impact the correlation of thrombosis with triple-positivity and the role of aCL and ab2GPI antibodies in addition to LAC. It has already been shown that the presence of aCL and ab2GPI of the same isotype reinforces the clinical probability of APS [32] . We confirmed that ORs for all platforms are higher for triple-positivity with concordance of isotype compared with triple-positivity including combinations of aCL and ab2GPI irrespective of isotype, except for one platform (QUANTA Lite ELISA Ò ) with lower OR for IgM triple-positivity compared with the OR for triplepositivity irrespective of the isotype.
Our results clearly illustrate the wide variation in thrombotic association introduced by aPL detection methods. In LAC positives, 'isolated' IgM or 'isolated' IgG aPL was less correlated with thrombosis than triple-positivity irrespective of the isotype. Interestingly, positivity for LAC, aCL and ab2GPI antibodies for both isotypes resulted in the strongest correlation with thrombosis. Therefore, both IgG and IgM antibodies are of added value in stratification of risk of thrombosis in APS. However, IgM did not add any value in thrombotic association to LAC positives in the absence of IgG aPL.
In conclusion, detection of triple-positivity varied among commercially available solid phase assays detecting aCL and ab2GPI antibodies. However, triple-positivity (irrespective of the isotype) was statistically correlated with thrombosis, independent of the solid phase assay used. Except for one platform, concordance of isotype resulted in the highest OR. Detection of IgM antibodies in triple-positivity was only of added clinical value in combination with LAC, aCL IgG and ab2GPI IgG positivity. These data confirm the high association of triplepositivity with thrombosis and show that the isotype and solid phase assay used to detect aPL affect the association with thrombosis. As triple-positive APS patients have an increased risk of thrombotic recurrence, standardization in triple-positivity detection is urgently warranted. 
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